Boston Scientific Corp. (BSX) Shares Sold by Enterprise Financial Services Corp
Enterprise Financial Services Corp decreased its stake in shares of Boston Scientific Corp. (NYSE:BSX) by 0.7% during the second quarter, Holdings Channel reports. The institutional investor owned 14,199 shares of the company’s stock after selling 101 shares during the period. Enterprise Financial Services Corp’s holdings in Boston Scientific Corp. were worth $332,000 as of its most recent SEC filing.
A number of other institutional investors also recently bought and sold shares of BSX. Wellington Management Group LLP boosted its position in Boston Scientific Corp. by 9.1% in the first quarter. Wellington Management Group LLP now owns 103,378,526 shares of the company’s stock valued at $1,944,549,000 after buying an additional 8,643,058 shares in the last quarter. Strs Ohio boosted its position in Boston Scientific Corp. by 1,154.5% in the second quarter. Strs Ohio now owns 846,118 shares of the company’s stock valued at $19,773,000 after buying an additional 778,670 shares in the last quarter. Bank of Montreal Can bought a new position in Boston Scientific Corp. during the second quarter valued at about $13,309,000. Bollard Group LLC boosted its position in Boston Scientific Corp. by 1.5% in the second quarter. Bollard Group LLC now owns 33,797,061 shares of the company’s stock valued at $789,837,000 after buying an additional 500,370 shares in the last quarter. Finally, Bellevue Group AG bought a new position in Boston Scientific Corp. during the first quarter valued at about $9,405,000. Institutional investors and hedge funds own 92.05% of the company’s stock.
Shares of Boston Scientific Corp. (NYSE:BSX) traded up 1.31% during mid-day trading on Tuesday, reaching $23.12. The company had a trading volume of 4,979,577 shares. Boston Scientific Corp. has a 1-year low of $15.67 and a 1-year high of $24.79. The company’s market capitalization is $31.46 billion. The stock’s 50-day moving average price is $23.64 and its 200 day moving average price is $22.79.
Boston Scientific Corp. (NYSE:BSX) last posted its quarterly earnings data on Thursday, July 28th. The company reported $0.27 EPS for the quarter, meeting the Zacks’ consensus estimate of $0.27. The business earned $2.13 billion during the quarter, compared to analysts’ expectations of $2.05 billion. Boston Scientific Corp. had a positive return on equity of 22.66% and a negative net margin of 4.34%. The business’s revenue was up 15.4% compared to the same quarter last year. During the same period in the previous year, the business earned $0.22 earnings per share. Equities analysts expect that Boston Scientific Corp. will post $1.10 EPS for the current year.
BSX has been the topic of several research analyst reports. Zacks Investment Research cut shares of Boston Scientific Corp. from a “buy” rating to a “hold” rating in a research note on Wednesday, August 31st. Citigroup Inc. upped their target price on shares of Boston Scientific Corp. from $26.00 to $28.00 and gave the company a “buy” rating in a research note on Wednesday, August 3rd. Credit Suisse Group AG restated a “buy” rating on shares of Boston Scientific Corp. in a research note on Friday, July 29th. Argus upgraded shares of Boston Scientific Corp. from a “hold” rating to a “buy” rating and upped their target price for the company from $23.82 to $33.00 in a research note on Thursday, September 1st. They noted that the move was a valuation call. Finally, Royal Bank Of Canada restated an “outperform” rating and set a $28.00 target price on shares of Boston Scientific Corp. in a research note on Friday. Five analysts have rated the stock with a hold rating and twenty-two have assigned a buy rating to the company. Boston Scientific Corp. currently has an average rating of “Buy” and a consensus price target of $25.19.
In other news, CEO Michael F. Mahoney sold 44,400 shares of the business’s stock in a transaction that occurred on Monday, August 1st. The stock was sold at an average price of $24.44, for a total value of $1,085,136.00. Following the completion of the sale, the chief executive officer now directly owns 1,388,177 shares in the company, valued at $33,927,045.88. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, SVP John Bradley Sorenson sold 2,500 shares of the business’s stock in a transaction that occurred on Thursday, August 11th. The shares were sold at an average price of $23.90, for a total value of $59,750.00. Following the completion of the sale, the senior vice president now owns 12,615 shares of the company’s stock, valued at $301,498.50. The disclosure for this sale can be found here. 1.31% of the stock is owned by insiders.
About Boston Scientific Corp.
Boston Scientific Corporation is a developer, manufacturer and marketer of medical devices that are used in a range of interventional medical specialties. The Company offers its products by seven core businesses: Interventional Cardiology, Peripheral Interventions (PI), Cardiac Rhythm Management (CRM), Electrophysiology (EP), Endoscopy, Urology and Pelvic Health, and Neuromodulation.
Want to see what other hedge funds are holding BSX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Boston Scientific Corp. (NYSE:BSX).
Receive News & Ratings for Boston Scientific Corp. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Boston Scientific Corp. and related companies with MarketBeat.com's FREE daily email newsletter.